06896.HK
Golden Throat Holdings Group Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 2.28
+0.44%Year over year
Reported trailing growth
- Revenue
- +9.0%
- EBITDA
- +3.2%
- EBIT
- -3.0%
- EPS
- +6.0%
- Free cash flow
- +1.9%
- Operating cash flow
- +17.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -1.7%
- EBITDA
- -7.4%
- EBIT
- -5.3%
- Net income
- -3.7%
- EPS
- -3.6%
- Free cash flow
- -32.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025